Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Growth Rate by Type: 2018 VS 2024 VS 2034
1.2.2 SGD-2083
1.2.3 Crizanlizumab
1.2.4 PF-04447943
1.2.5 NVX-508
1.2.6 Others
1.3 Market by Application
1.3.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Application: 2018 VS 2024 VS 2034
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2018-2034)
2.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size across Key Geographies Worldwide: 2018 VS 2024 VS 2034
2.3 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region (2018-2023)
2.4 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Countries Ranking by Market Size
3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Competitive by Company
3.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Players
3.1.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Players (2018-2023)
3.1.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Players (2018-2023)
3.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue
3.4 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Concentration Ratio
3.4.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in 2024
3.5 Global Key Players of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Head office and Area Served
3.6 Global Key Players of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug, Product and Application
3.7 Global Key Players of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Breakdown Data by Type
4.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Historic Revenue by Type (2018-2023)
4.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Forecasted Revenue by Type (2024-2034)
5 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Breakdown Data by Application
5.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Historic Market Size by Application (2018-2023)
5.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Company (2021-2023)
6.2 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2018-2034)
6.3 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2018-2034)
6.4 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2018-2034)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Company (2021-2023)
7.2 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2018-2034)
7.3 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2018-2034)
7.4 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Company (2021-2023)
8.2 Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2018-2034)
8.3 Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2018-2034)
8.4 Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Company (2021-2023)
9.2 Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2018-2034)
9.3 Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2018-2034)
9.4 Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Company (2021-2023)
10.2 Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2018-2034)
10.3 Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2018-2034)
10.4 Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 AstraZeneca Plc
11.1.1 AstraZeneca Plc Company Details
11.1.2 AstraZeneca Plc Business Overview
11.1.3 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Products and Services
11.1.4 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
11.1.5 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
11.1.6 AstraZeneca Plc Recent Development
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Details
11.2.2 Bristol-Myers Squibb Company Business Overview
11.2.3 Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Products and Services
11.2.4 Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
11.2.5 Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
11.2.6 Bristol-Myers Squibb Company Recent Development
11.3 Gilead Sciences Inc
11.3.1 Gilead Sciences Inc Company Details
11.3.2 Gilead Sciences Inc Business Overview
11.3.3 Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Products and Services
11.3.4 Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
11.3.5 Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
11.3.6 Gilead Sciences Inc Recent Development
11.4 Modus Therapeutics Holding AB
11.4.1 Modus Therapeutics Holding AB Company Details
11.4.2 Modus Therapeutics Holding AB Business Overview
11.4.3 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Products and Services
11.4.4 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
11.4.5 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
11.4.6 Modus Therapeutics Holding AB Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Details
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Products and Services
11.5.4 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
11.5.5 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
11.5.6 Novartis AG Recent Development
11.6 NuvOx Pharma LLC
11.6.1 NuvOx Pharma LLC Company Details
11.6.2 NuvOx Pharma LLC Business Overview
11.6.3 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Products and Services
11.6.4 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
11.6.5 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
11.6.6 NuvOx Pharma LLC Recent Development
11.7 Pfizer Inc
11.7.1 Pfizer Inc Company Details
11.7.2 Pfizer Inc Business Overview
11.7.3 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Products and Services
11.7.4 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
11.7.5 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
11.7.6 Pfizer Inc Recent Development
11.8 Seattle Genetics Inc
11.8.1 Seattle Genetics Inc Company Details
11.8.2 Seattle Genetics Inc Business Overview
11.8.3 Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Products and Services
11.8.4 Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
11.8.5 Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
11.8.6 Seattle Genetics Inc Recent Development
12 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Dynamics
12.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Trends
12.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Drivers
12.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Challenges
12.4 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2024 VS 2034
Table 2. Key Players of SGD-2083
Table 3. Key Players of Crizanlizumab
Table 4. Key Players of PF-04447943
Table 5. Key Players of NVX-508
Table 6. Key Players of Others
Table 7. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Growth Rate by Application (US$ Million), 2018 VS 2024 VS 2034
Table 8. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2024 VS 2034
Table 9. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Region (2018-2023) & (US$ Million)
Table 10. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 11. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size of Top 10 Countries, 2018 VS 2024 VS 2034, (US$ Million)
Table 12. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Players (2018-2023) & (US$ Million)
Table 13. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Players (2018-2023)
Table 14. Global Top Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug as of 2024)
Table 15. Ranking of Global Top Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Companies by Revenue (US$ Million) in 2024
Table 16. Global 5 Largest Players Market Share by Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (CR5 and HHI) & (2018-2023)
Table 17. Global Key Players of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug, Headquarters and Area Served
Table 18. Global Key Players of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug, Product and Application
Table 19. Global Key Players of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug, Date of Enter into This Industry
Table 20. Mergers & Acquisitions, Expansion Plans
Table 21. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2018-2023) & (US$ Million)
Table 22. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2018-2023)
Table 23. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 24. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2024-2034)
Table 25. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2018-2023) & (US$ Million)
Table 26. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2018-2023)
Table 27. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 28. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2024-2034)
Table 29. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Company (2021-2023) & (US$ Million)
Table 30. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 31. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 32. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 33. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 34. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 35. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2018-2023) & (US$ Million)
Table 36. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2024-2034) & (US$ Million)
Table 37. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Company (2021-2023) & (US$ Million)
Table 38. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 39. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 40. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 41. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 42. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 43. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2018-2023) & (US$ Million)
Table 44. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2024-2034) & (US$ Million)
Table 45. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Company (2021-2023) & (US$ Million)
Table 46. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 47. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 48. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 49. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 50. Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 51. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Region (2018-2023) & (US$ Million)
Table 52. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Region (2024-2034) & (US$ Million)
Table 53. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Company (2021-2023) & (US$ Million)
Table 54. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 55. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 56. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 57. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 58. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 59. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2018-2023) & (US$ Million)
Table 60. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2024-2034) & (US$ Million)
Table 61. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Company (2021-2023) & (US$ Million)
Table 62. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 63. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Type (2024-2034) & (US$ Million)
Table 64. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 65. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Application (2024-2034) & (US$ Million)
Table 66. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 67. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2018-2023) & (US$ Million)
Table 68. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue by Country (2024-2034) & (US$ Million)
Table 69. AstraZeneca Plc Company Details
Table 70. AstraZeneca Plc Business Overview
Table 71. AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Services
Table 72. AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023) & (US$ Million)
Table 73. AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
Table 74. AstraZeneca Plc Recent Development
Table 75. Bristol-Myers Squibb Company Company Details
Table 76. Bristol-Myers Squibb Company Business Overview
Table 77. Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Services
Table 78. Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023) & (US$ Million)
Table 79. Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
Table 80. Bristol-Myers Squibb Company Recent Development
Table 81. Gilead Sciences Inc Company Details
Table 82. Gilead Sciences Inc Business Overview
Table 83. Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Services
Table 84. Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023) & (US$ Million)
Table 85. Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
Table 86. Gilead Sciences Inc Recent Development
Table 87. Modus Therapeutics Holding AB Company Details
Table 88. Modus Therapeutics Holding AB Business Overview
Table 89. Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Services
Table 90. Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023) & (US$ Million)
Table 91. Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
Table 92. Modus Therapeutics Holding AB Recent Development
Table 93. Novartis AG Company Details
Table 94. Novartis AG Business Overview
Table 95. Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Services
Table 96. Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023) & (US$ Million)
Table 97. Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
Table 98. Novartis AG Recent Development
Table 99. NuvOx Pharma LLC Company Details
Table 100. NuvOx Pharma LLC Business Overview
Table 101. NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Services
Table 102. NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023) & (US$ Million)
Table 103. NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
Table 104. NuvOx Pharma LLC Recent Development
Table 105. Pfizer Inc Company Details
Table 106. Pfizer Inc Business Overview
Table 107. Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Services
Table 108. Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023) & (US$ Million)
Table 109. Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
Table 110. Pfizer Inc Recent Development
Table 111. Seattle Genetics Inc Company Details
Table 112. Seattle Genetics Inc Business Overview
Table 113. Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product and Services
Table 114. Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023) & (US$ Million)
Table 115. Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug SWOT Analysis
Table 116. Seattle Genetics Inc Recent Development
Table 117. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Trends
Table 118. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Drivers
Table 119. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Challenges
Table 120. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Restraints
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Picture
Figure 2. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (US$ Million): 2018 VS 2024 VS 2034
Figure 3. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Type: 2024 VS 2034
Figure 4. SGD-2083 Features
Figure 5. Crizanlizumab Features
Figure 6. PF-04447943 Features
Figure 7. NVX-508 Features
Figure 8. Others Features
Figure 9. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (US$ Million): 2018 VS 2024 VS 2034
Figure 10. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Application: 2024 VS 2034
Figure 11. Clinic
Figure 12. Hospital
Figure 13. Others
Figure 14. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Report Years Considered
Figure 15. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 16. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size 2018-2034 (US$ Million)
Figure 17. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Market Share by Region: 2024 VS 2034
Figure 18. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Region in 2018 VS 2024
Figure 19. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share Forecast by Region (2024-2034)
Figure 20. Global Top 10 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Countries Ranking by Market Size (US$ Million) in 2024
Figure 21. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size of Top 10 Countries, 2018 VS 2024 VS 2034, (US$ Million)
Figure 22. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Players in 2024
Figure 23. Global Top Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug as of 2024)
Figure 24. The Top 10 and 5 Players Market Share by Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue in 2024
Figure 25. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Company in 2024
Figure 26. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2018-2034)
Figure 27. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2018-2034)
Figure 28. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Country (2018-2034)
Figure 29. U.S. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 30. Canada Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 31. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Company in 2024
Figure 32. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2018-2034)
Figure 33. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2018-2034)
Figure 34. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Country (2018-2034)
Figure 35. Germany Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 36. France Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 37. U.K. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 38. Italy Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 39. Russia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 40. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Company in 2024
Figure 41. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2018-2034)
Figure 42. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2018-2034)
Figure 43. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Region (2018-2034)
Figure 44. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 45. Japan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 46. South Korea Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 47. India Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 48. Australia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 49. Taiwan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 50. Indonesia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 51. Thailand Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 52. Malaysia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 53. Philippines Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 54. Vietnam Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 55. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Company in 2024
Figure 56. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2018-2034)
Figure 57. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2018-2034)
Figure 58. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Country (2018-2034)
Figure 59. Mexico Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 60. Brazil Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 61. Argentina Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 62. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Company in 2024
Figure 63. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2018-2034)
Figure 64. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2018-2034)
Figure 65. Middle East and Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Share by Country (2018-2034)
Figure 66. Turkey Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 67. Saudi Arabia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 68. UAE Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue (2018-2034) & (US$ Million)
Figure 69. AstraZeneca Plc Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
Figure 70. Bristol-Myers Squibb Company Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
Figure 71. Gilead Sciences Inc Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
Figure 72. Modus Therapeutics Holding AB Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
Figure 73. Novartis AG Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
Figure 74. NuvOx Pharma LLC Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
Figure 75. Pfizer Inc Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
Figure 76. Seattle Genetics Inc Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2018-2023)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed